Huang Jianxiang found that in HCC patients with microvascular invasion, combined camrelizumab therapy based on TACE treatment, VEGF, OPN, and Egfl7 levels were substantially decreased at 1 month and 3 months after surgery compared to before treatment and the degree of reduction was higher than in patients treated with TACE alone, and the quality of life was higher in patients treated with combination therapy. This evidence concerns the gene SPP1 and hepatocellular carcinoma.